Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 10Terminated 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Rectal Neoplasms 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Semaxinib × Clear all
NCT00006001 2013-06-03

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
37 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00006003 2013-01-24

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Dermatologic

Melanoma

NCT00009919 2013-01-23

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

National Cancer Institute (NCI)

Phase 2 Terminated
50 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡